Literature DB >> 12111882

Designing complex group sequential survival trials.

Edward Lakatos1.   

Abstract

This paper presents methodology for designing complex group sequential survival trials when the survival curves will be compared using the logrank statistic. The method can be applied to any treatment and control survival curves as long as each hazard function can be approximated by a piecewise linear function. The approach allows arbitrary accrual patterns and permits adjustment for varying rates of non-compliance, drop-in and loss to follow-up. The calendar-time-information-time transformation is derived under these complex assumptions. This permits the exploration of the operating characteristics of various interim analysis plans, including sample size and power. By using the calendar-time-information-time transformation, information fractions corresponding to desired calendar times can be determined. In this way, the interim analyses can be scheduled in information time, assuring the desired power and realization of the spending function, while the interim analyses will take place according to the desired calendar schedule. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2002        PMID: 12111882     DOI: 10.1002/sim.1193

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.

Authors:  Milind A Phadnis; James B Wetmore; Matthew S Mayo
Journal:  Stat Med       Date:  2017-08-16       Impact factor: 2.373

2.  Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation.

Authors:  Elana J Bernstein; Joan M Bathon; David J Lederer
Journal:  Rheumatology (Oxford)       Date:  2018-05-01       Impact factor: 7.580

3.  Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.

Authors:  Jeannette Y Lee; Shelly Y Lensing; J Michael Berry-Lawhorn; Naomi Jay; Teresa M Darragh; Stephen E Goldstone; Timothy J Wilkin; Elizabeth A Stier; Mark Einstein; Julia C Pugliese; Joel M Palefsky
Journal:  Contemp Clin Trials       Date:  2022-01-10       Impact factor: 2.226

4.  Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.

Authors:  Susan Halabi
Journal:  J Biom Biostat       Date:  2012-05-19

5.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10

6.  High circulating VEGF level predicts poor overall survival in lung cancer.

Authors:  Pingping Hu; Weidong Liu; Liguang Wang; Miaomiao Yang; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

7.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

8.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

9.  Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection.

Authors:  P Hu; G Wang; H Cao; H Ma; P Sui; J Du
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

10.  The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study.

Authors:  Jean-Pierre Quenot; Christine Binquet; Fady Kara; Olivier Martinet; Frederique Ganster; Jean-Christophe Navellou; Vincent Castelain; Damien Barraud; Joel Cousson; Guillaume Louis; Pierre Perez; Khaldoun Kuteifan; Alain Noirot; Julio Badie; Chaouki Mezher; Henry Lessire; Arnaud Pavon
Journal:  Crit Care       Date:  2013-04-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.